<DOC>
	<DOCNO>NCT00859586</DOCNO>
	<brief_summary>Patients receive allogeneic stem cell transplantation hematological malignancy suffer relapse disease post-transplant limited treatment option poor prognosis . With exception patient chronic leukemia may achieve prolonged remission donor lymphocyte infusion ( DLIs ) , treatments use either chemotherapy DLI achieve le 10 % median survival beyond 6 month . Most patient die progressive leukemia , underlie need new therapeutic approach . Human leukocyte antigen ( HLA ) -mismatched DLIs appear possess potent graft-versus-leukemia ( GvL ) effect . However , give HLA-mismatched transplant DLIs high risk cause graft-versus-host disease ( GvHD ) , severe . To reduce risk GvHD , infusion mismatch lymphocyte alternative donor may use avoid permanent engraftment associate risk GvHD . In study , propose use novel strategy treat leukemias relapse HLA match allogeneic stem cell transplantation use haplo-identical DLIs promote associate antileukemic effect minimize possibility permanent engraftment associate GvHD . To achieve temporary engraftment promote disease control give fludarabine immunosuppression prior DLI . We anticipate infusion HLA-mismatched donor lymphocyte set produce detectible engraftment temporary engraftment , may result strong GvL effect regardless engraftment outcome . We select patient protocol fall bad category post-transplant relapse . Specifically , enroll patient acute leukemia MDS relapsing within 6 month transplant , less 5 % survive beyond year relapse .</brief_summary>
	<brief_title>Mismatched Donor Lymphocyte Infusions Relapsed Disease Following Allogeneic Stem Cell Transplantation</brief_title>
	<detailed_description>Patients receive allogeneic stem cell transplantation hematological malignancy suffer relapse disease post-transplant limited treatment option poor prognosis . With exception patient chronic leukemia may achieve prolonged remission donor lymphocyte infusion ( DLIs ) , treatments use either chemotherapy DLI achieve le 10 % median survival beyond 6 month . Most patient die progressive leukemia , underlie need new therapeutic approach . HLA-mismatched DLIs appear possess potent graft-versus-leukemia ( GvL ) effect . However , give HLA-mismatched transplant DLIs high risk cause graft-versus-host disease ( GvHD ) , severe . To reduce risk GvHD , infusion mismatch lymphocyte alternative donor may use avoid permanent engraftment associate risk GvHD . In study , propose use novel strategy treat leukemias relapse HLA match allogeneic stem cell transplantation use haplo-identical DLIs promote associate antileukemic effect minimize possibility permanent engraftment associate GvHD . To achieve temporary engraftment promote disease control give fludarabine immunosuppression prior DLI . We anticipate infusion HLA-mismatched donor lymphocyte set produce detectible engraftment temporary engraftment , may result strong GvL effect regardless engraftment outcome . We select patient protocol fall bad category post-transplant relapse . Specifically , enroll patient acute leukemia MDS relapsing within 6 month transplant , less 5 % survive beyond year relapse . The primary objective phase II clinical trial evaluate safety efficacy use non-engraftment model lymphocytes infusion haplo-identical donor treat relapse disease follow match sibling stem cell transplantation subject candidate alternative treatment option . We therefore propose phase II clinical trial evaluate safety efficacy infusion unmanipulated lymphocytes haplo-identical donor subject relapse disease follow match sibling stem cell transplantation candidate alternative treatment option . The primary endpoint phase 2 study survival 6 month post-relapse disease . Successful outcome study survival 100 % great National Heart Lung Blood ( NHLBI ) historical 25 % 6-months . Secondary endpoint include : incidence severity induce GvHD , proportion DLI engraftment , peak chimerism , leukemia response 21 day post DLI , residual leukemia measure patient chimerism , leukemia free survival date relapse , safety mismatch DLI procedure .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<criteria>ELIGIBILITY CRITERIA : Inclusion Criteria Recipient : 1 . Diagnosed one follow hematological condition : Acute lymphoblastic leukemia ( ALL ) subtype Acute myelogenous leukemia ( AML ) subtype Myelodysplastic syndrome ( MDS ) subtype Blastic phase CML 2 . Relapsed disease within 6 month match sibling allogeneic stem cell transplant procedure 3 . Evaluation protocol within 8 week relapse enrollment within 12 week relapse 4 . 875 year age 5 . Availability previous HLA identical ( 6/6 ) relate donor ( age 8 17 must previously donate bone marrow [ peripheral blood ] 6 . At least one haploidentical ( 13 antigen mismatch ) relate donor available apheresis Exclusion Criteria Recipient ( follow ) : 1 . Active grade IIIV GvHD 2 . Extensive chronic GvHD 3 . Posttransplant DLI original donor within 1 month protocol enrollment . 4 . Progressive disease despite postrelapse chemo monoclonal therapy . 5 . Comorbidity severity would preclude patient ability tolerate protocol therapy . 6 . AST/SGOT great 10 x ULN ( grade 3 , CTCAE ) . 7 . Bilirubin great 5 x ULN ( grade 3 , CTCAE ) . 8 . Creatinine great 3.5 mg/dl ( grade 3 , CTCAE ) . 9 . HIV positive ( Recipients positive hepatitis B ( HBV ) , hepatitis C ( HCV ) human Tcell lymphotropic virus ( HTLVI/II ) exclude participation ) . 10 . Positive pregnancy test woman childbearing age . 11 . Severe psychiatric illness mental deficiency sufficiently severe make compliance transplant treatment unlikely informed consent impossible . Inclusion Criteria Stem Cell Donors : 1 . HLAmatched sibling stem cell donor original transplant participate stem cell rescue set severe , refractory GvHD cause haploidentical cell . 2 . Related HLA haploidentical ( 13 A , B DR antigens mismatch recipient ) . To maximize GvL associate HLA disparity , haploidentical donor chosen base great HLA mismatch ( preference : 3/6 great 4/6 great 5/6 ) . Parents sibling consider equally . 3 . Weight great equal 18 kg 4 . Age great equal 8 less equal 80 year old . Exclusion Criteria Stem Cell Donor ( follow ) : 1 . Pregnant lactate 2 . Unfit receive filgrastim ( GCSF ) previous filgrastim mobilization donor 18 year age . 3 . Unfit undergo apheresis ( abnormal blood count , history stroke , uncontrolled hypertension ) . 4 . Sickling hemoglobinopathy HbSS HbSC . 5 . HIV positive . Donors positive hepatitis B ( HBV ) , hepatitis C ( HCV ) , human Tcell lymphotropic virus ( HTLVI/II ) , T.cruzi ( Chagas ) use discretion investigator follow counsel approval recipient . 6 . Severe psychiatric illness mental deficiency sufficiently severe make compliance donation stem cell unlikely and/or inform consent impossible . Inclusion criterion Haplo Lymphocyte Donors : 1 . Related HLA haploidentical ( 13 A , B DR antigens mismatch recipient ) . To maximize GvL associate HLA disparity , haploidentical donor chosen base great HLA mismatch ( preference : 3/6 great 4/6 great 5/6 ) . Donors age less 80 year require , parent sibling consider equally . 2 . Age great equal 18 less equal 80 year old . Exclusion Criteria Haplo Lymphocyte Donor ( follow ) : 1 . Pregnant lactate 2 . Unfit undergo apheresis ( abnormal blood count , history stroke , uncontrolled hypertension ) . &lt; TAB &gt; 3 . Sickling hemoglobinopathy HbSS HbSC . 4 . HIV positive . Donors positive hepatitis B ( HBV ) , hepatitis C ( HCV ) human Tcell lymphotropic virus ( HTLVI/II ) , T.cruzi ( Chagas ) use discretion investigator follow counsel approval recipient . 5 . Severe psychiatric illness mental deficiency sufficiently severe make compliance donation stem cell unlikely and/or inform consent impossible</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Acute Myelogenous Leukemia ( AML )</keyword>
	<keyword>Acute Lymphoblastic Leukemia ( ALL )</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>Myelodysplastic Syndrome ( MDS )</keyword>
	<keyword>Acute Myelogenous Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
	<keyword>ALL</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>MDS</keyword>
</DOC>